New Data Support Boost in ER-/HER2- Breast Cancer
At ESTRO 2025, Anders Winther Mølby Nielsen, MD, PhD student at Aarhus University, presented a post-hoc analysis from the DBCG IMN2 study. The findings show that older breast cancer patients with ER-negative/HER2-negative tumors had a notably higher risk of local recurrence when treated without a tumor bed boost. Based on these results, Danish guidelines now recommend boost radiation for this subgroup, regardless of age.
Få tillgång
Om du är läkare, sjuksköterska eller annan vårdpersonal kan du komma åt hela artikeln genom att skapa en profil på BestPractice Nordic.
- Få tillgång
- Om du redan har en profil: Logga in